Walbert Keli
SEC insider (Form 3/4/5 filer). CIK 0002051489. Director at Hemab Therapeutics Holdings, Inc. (COAG) and 2 other issuers. 9 reported Form 4/5 transactions since Sep 2024; latest on Sep 24, 2026. Located in CAMBRIDGE, MA.
Companies Walbert Keli has filed insider reports for
- Hemab Therapeutics Holdings, Inc. (COAG): Director
- SPRUCE BIOSCIENCES, INC. (SPRB): Director
- Apellis Pharmaceuticals, Inc. (APLS): Director
Walbert Keli
CIK: 0002051489
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Sep 24, 2026COAG
Hemab Therapeutics Holdings, Inc.
AwardDirectStock Option (Right to Buy)
36K shares- - May 21, 2026SPRB
SPRUCE BIOSCIENCES, INC.
AwardDirectStock Option (Right to Buy)
1.7K shares- - May 14, 2026APLS
Apellis Pharmaceuticals, Inc.
DispositionDirect664 shares- - May 14, 2026APLS
Apellis Pharmaceuticals, Inc.
DispositionDirect7.3K shares- - May 14, 2026APLS
Apellis Pharmaceuticals, Inc.
Tender OfferDirect17.1K shares- - May 14, 2026APLS
Apellis Pharmaceuticals, Inc.
DispositionDirect8.3K shares- - Jan 1, 2026APLS
Apellis Pharmaceuticals, Inc.
AwardDirect8K shares- - Dec 11, 2025SPRB
SPRUCE BIOSCIENCES, INC.
AwardDirectStock Option (Right to Buy)
3.4K shares- - Jan 8, 2025APLS
Apellis Pharmaceuticals, Inc.
AwardDirect9.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 24, 2026 |  COAG Hemab Therapeutics Holdings, Inc. | Award Stock Option (Right to Buy) | 36,000 | - | - | Direct |
| May 21, 2026 |  SPRB SPRUCE BIOSCIENCES, INC. | Award Stock Option (Right to Buy) | 1,700 | - | - | Direct |
| May 14, 2026 |  APLS Apellis Pharmaceuticals, Inc. | Disposition | 664 | - | $0 | Direct |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | Disposition | 7,297 | - | $0 | Direct |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | Tender Offer | 17,051 | - | $0 | Direct |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | Disposition | 8,332 | - | $0 | Direct |
| Jan 1, 2026 | APLS Apellis Pharmaceuticals, Inc. | Award | 7,961 | - | $0 | Direct |
| Dec 11, 2025 | SPRB SPRUCE BIOSCIENCES, INC. | Award Stock Option (Right to Buy) | 3,400 | - | - | Direct |
| Jan 8, 2025 | APLS Apellis Pharmaceuticals, Inc. | Award | 9,090 | - | $0 | Direct |
1-9 of 9 transactions